J9298 Nivolumab & relatlimab-rmbw - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Nivolumab & relatlimab-rmbw

Brand Name:

Opdualag

Strength:

3mg/1mg

HCPCS:

J9298

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Checkpoint Inhibitor

Monoclonal Antibody

Minor Drug Class:

PD-1

LAG3

Oral (Y/N):

No

FDA Approval Year:

2022

FDA Discontinuation Year:

CMS Effective Date:

Sept. 27, 2022

CMS Discontinuation Date:

Status:

In Use